cimadronate has been researched along with Prostatic Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asahi, H; Komatsu, K; Koshida, K; Maeda, Y; Mizokami, A; Namiki, M | 1 |
| Futakuchi, M; Hikosaka, A; Kohri, K; Ogiso, T; Shirai, T; Suzuki, S | 1 |
| Koiso, K; Nemoto, R; Nishijima, Y; Uchida, K | 1 |
3 other study(ies) available for cimadronate and Prostatic Neoplasms
| Article | Year |
|---|---|
Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Diphosphonates; Drug Resistance, Neoplasm; Drug Therapy, Combination; Estramustine; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 2003 |
Lack of prophylactic effect of incadronate on skeletal lesions associated with implants of prostate cancer.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Male; Neoplasm Transplantation; Prostatic Neoplasms; Rats; Rats, Inbred F344; Treatment Failure | 2006 |
Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice.
Topics: Animals; Bone Resorption; Carcinoma, Transitional Cell; Diphosphonates; Female; Humans; Male; Mice; Mice, Inbred C3H; Mice, Nude; Prostatic Neoplasms; Tumor Cells, Cultured | 1993 |